2014

MarketVIEW: Dengue vaccines

NEW YORK, Feb. 18, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

MarketVIEW: Dengue vaccines

http://www.reportlinker.com/p0961686/MarketVIEW-Dengue-vaccines.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Dengue fever (DF) is a mosquito-borne disease (Aedes) which can affect two fifths of the world's population. DF infection has a wide spectrum of symptoms that range from a mild febrile illness to severe outcomes, even death as observed in dengue haemorrhagic fever (DHF) and dengue shock syndrome (DSS). Importantly, of the 22,000 estimated deaths per year, the large majority are in children (< 15yrs) where no specific treatment is available.

This MarketVIEW product forecasts the potential commercial value of dengue fever vaccine(s) across endemic and travelers markets to 2030. The model(s) contain value ($ m) and volume (mio doses) predictions for endemic countries in all age segments in both the public and private sector. LO and HI forecast scenarios which include expected demand from country selected catch-up campaigns are also detailed along with discussion of development considerations of the ideal dengue vaccine(s) in light of current pipeline candidates.

THIS PRODUCT IS TWO EXECUTIVE PRESENTATIONS + TWO MODELS 

Contents – Summary presentation (MS PowerPoint based)Author's noteExecutive SummaryCommercial model – key outputsSummary for total number of CDI cases (theoretical and treated) in Emerging + ROW region2020 Snapshot CDI cases (theoretical)Deploying C.diff vaccines: primary prevention (PX)C.diff vaccines: three potential markets modelledPX indication (community) – total predicted demand (doses 000s)PX indication (community) – total available market ($ USD 000s)PX indication (hospital admission) – total available market ($ USD 000s)TX indication (hospital) – total predicted demand (doses 000s)TX indication (hospital) – total available market ($ USD 000s)C.diff vaccines: total commercial summary (peak)C.diff vaccines – key model assumptionsC.diff vaccines – countries included in modelCommunity prophylaxis – major model assumptionsPrevention of CDI recurrences (TX) – major model assumptionsHospital prophylaxis – major model assumptionsPrimary research – summary of findingsC.diff (CDI) situation analysisPrimary research respondentsExpert viewpoints: nosocomial infections in generalExpert viewpoints: major pathogensExpert viewpoints: reporting surveillanceBrazil: National Health Surveillance Agency (ANVISA)Mexico: National Health Surveillance Agency (SALUD)Expert viewpoints: nosocomial infections – incidence estimatesExpert viewpoints: awareness of Clostridium difficileExpert viewpoints: is CDI a growing problem?Expert viewpoints: test for Clostridium difficileExpert viewpoints: C.diff molecular epidemiologyC.diff as a % of nosocomial diarrhea – Emerging markets/ROW regionExpert viewpoints: treating CDICountry environment factors contributing to CDIExpert viewpoints: (use) misuse of antibioticsExpert viewpoints: role of hospitals (LOS)Expert viewpoints: elderly care/the role of nursing homesOther notable patient factorsExpert Reaction to C.diff R&D pipeline and vaccinesCDI pipeline: by estimated filing dateExpert viewpoints: CDI R&D pipeline (all)Expert viewpoints: C.diff vaccines – general commentsExpert viewpoints: deploying C.diff vaccinesExpert viewpoints: funding C.diff vaccinesBack-up and source materialCDI – Western marketsDefinition of at-risk population (community vaccination)About VacZine AnalyticsDisclaimerPAGES: 60 MS PowerPoint slides, fully referenced/sourced. Available in .pdf formContents – Vaccine demand model (MS Excel-based)Title sheetCHARTS (PX) comm.CHARTS (PX) hospCHARTS (TX)CHARTS (Epi)Val/Vol summary (PX comm)Val/Vol summary (PX hosp)Val/Vol summary (TX)Vaccine pricing forecastEpi summary – CDIProphylaxis (hosp admission)All admissions (>65 yrs)Emer admissions (>65yrs)Elect admissions (>65yrs)PX > 65yrs (comm) and TX (RD – first line)BrazilRussiaIndiaChinaArgentinaChileColumbiaVenezuelaTurkeySaudi ArabiaPolandCzech RepublicSlovakiaHungarySouth AfricaMalaysiaSingaporeIndonesiaPhilippinesThailandSouth KoreaSource materialNosocomial diarrhea (CDIFF)Hospital admissions forecastHospital beds – admissionsChina – hospital statisticsBrazil – hospital statisticsHospital beds (historical)Hospital discharges (historical)Population database (all ages)Population database (65 – 90 yrs)Hospital admission breakdown by typeBack-pageWORKSHEETS: ~65

To order this report:: MarketVIEW: Dengue vaccines

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.